|
1
|
Kimby E, Nygren P and Glimelius B;
SBU-group. Swedish Council of Technology Assessment in Health Care.
A systematic overview of chemotherapy effects in acute myeloid
leukaemia. Acta Oncol. 40:231–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tallman MS, Gilliland DG and Rowe JM: Drug
therapy for acute myeloid leukemia. Blood. 106:1154–1163. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pulte D, Gondos A and Brenner H: Expected
long-term survival of patients diagnosed with acute myeloblastic
leukemia during 2006–2010. Ann Oncol. 21:335–341. 2010.
|
|
4
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim LP, Lau NC, Garrett-Engele P, et al:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JK, Noh JH, Jung KH, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou M, Liu Z, Zhao Y, et al:
MicroRNA-125b confers the resistance of breast cancer cells to
paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist
killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuxia M, Zhennan T and Wei Z: Circulating
miR-125b is a novel biomarker for screening non-small-cell lung
cancer and predicts poor prognosis. J Cancer Res Clin Oncol.
138:2045–2050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nishida N, Yokobori T, Mimori K, et al:
MicroRNA miR-125b is a prognostic marker in human colorectal
cancer. Int J Oncol. 38:1437–1443. 2011.PubMed/NCBI
|
|
13
|
Bousquet M, Quelen C, Rosati R, et al:
Myeloid cell differentiation arrest by miR-125b-1 in
myelodysplastic syndrome and acute myeloid leukemia with the
t(2;11)(p21;q23) translocation. J Exp Med. 205:2499–2506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Enomoto Y, Kitaura J, Hatakeyama K, et al:
Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.
Leukemia. 25:1849–1856. 2011.
|
|
15
|
Klusmann JH, Li Z, Böhmer K, et al:
miR-125b-2 is a potential oncomiR on human chromosome 21 in
megakaryoblastic leukemia. Genes Dev. 24:478–490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gefen N, Binder V, Zaliova M, et al:
Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1
(TEL/AML1) leukemias and confers survival advantage to growth
inhibitory signals independent of p53. Leukemia. 24:89–96. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA, Liu CG, Sevignani C, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H, Luo XQ, Feng DD, et al:
Upregulation of microRNA-125b contributes to leukemogenesis and
increases drug resistance in pediatric acute promyelocytic
leukemia. Mol Cancer. 10:1082011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schotte D, De Menezes RX, Akbari Moqadam
F, et al: MicroRNA characterize genetic diversity and drug
resistance in pediatric acute lymphoblastic leukemia.
Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Döhner H, Estey EH, Amadori S, et al;
European LeukemiaNet. Diagnosis and management of acute myeloid
leukemia in adults: recommendations from an international expert
panel, on behalf of the European LeukemiaNet. Blood. 115:453–474.
2010.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Starczynowski DT, Kuchenbauer F,
Argiropoulos B, et al: Identification of miR-145 and miR-146a as
mediators of the 5q-syndrome phenotype. Nat Med. 16:49–58. 2010.
View Article : Google Scholar
|
|
23
|
Hughes MS, Yu YY, Dudley ME, et al:
Transfer of a TCR gene derived from a patient with a marked
antitumor response conveys highly active T-cell effector functions.
Hum Gene Ther. 16:457–472. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stark A, Brennecke J, Russell RB and Cohen
SM: Identification of Drosophila MicroRNA targets. PLoS
Biol. 1:397–409. 2003.
|
|
25
|
Husted S, Søkilde R, Rask L, et al:
MicroRNA expression profiles associated with development of drug
resistance in Ehrlich ascites tumor cells. Mol Pharm. 8:2055–2062.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rajabi H, Jin C, Ahmad R, McClary C, Joshi
MD and Kufe D: Mucin 1 oncoprotein expression is suppressed by the
miR-125b oncomir. Genes Cancer. 1:62–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iida K, Fukushi J, Matsumoto Y, et al:
miR-125b develops chemoresistance in Ewing sarcoma/primitive
neuroectodermal tumor. Cancer Cell Int. 13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong F, Sun C, Wang Z, et al: miR-125b
confers resistance of ovarian cancer cells to cisplatin by
targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ
Sci Technolog Med Sci. 31:543–549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Richardson DS and Johnson SA:
Anthracyclines in haematology: preclinical studies, toxicity and
delivery systems. Blood Rev. 11:201–223. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong J, Zhang JP, Li B, et al:
MicroRNA-125b promotes apoptosis by regulating the expression of
Mcl-1, Bcl-w and IL-6R. Oncogene. 32:3071–3079. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi L, Zhang S, Feng K, et al:
MicroRNA-125b-2 confers human glioblastoma stem cells resistance to
temozolomide through the mitochondrial pathway of apoptosis. Int J
Oncol. 40:119–129. 2012.PubMed/NCBI
|
|
32
|
Balakrishnan A, Stearns AT, Park PJ, et
al: Upregulation of proapoptotic microRNA mir-125a after massive
small bowel resection in rats. Ann Surg. 255:747–753. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeng CW, Zhang XJ, Lin KY, et al:
Camptothecin induces apoptosis in cancer cells via
microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol.
81:578–586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang F, Liu T, He Y, et al: MiR-125b
promotes proliferation and migration of type II endometrial
carcinoma cells through targeting TP53INP1 tumor suppressor in
vitro and in vivo. BMC Cancer. 11:4252011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SW, Ramasamy K, Bouamar H, Lin AP,
Jiang D and Aguiar RC: MicroRNAs miR-125a and miR-125b
constitutively activate the NF-κB pathway by targeting the tumor
necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl
Acad Sci USA. 109:7865–7870. 2012.PubMed/NCBI
|
|
36
|
Tan G, Niu J, Shi Y, Ouyang H and Wu ZH:
NF-κB-dependent microRNA-125b up-regulation promotes cell survival
by targeting p38α upon ultraviolet radiation. J Biol Chem.
287:33036–33047. 2012.
|
|
37
|
Bousquet M, Nguyen D, Chen C, et al:
MicroRNA-125b transforms myeloid cell lines by repressing multiple
mRNA. Haematologica. 97:1713–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
